A novel 2-stage approach that detects complement activation in patients with antiphospholipid antibody syndrome

Thrombosis Research

Volumn 156, Issue , 2017, Pages 119-125

  Rand, Jacob H ^a   Wu, Xiao Xuan ^a   Wolgast, Lucia R ^b   Lei, Victor ^c   Conway, Edward M ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Autoantibodies; Complement activation; Phospholipids; Thrombosis; Vascular endothelial cells

Indexed keywords

BETA2 GLYCOPROTEIN 1; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5B; ECULIZUMAB; IMMUNOGLOBULIN G; PHOSPHOLIPID; PHOSPHOLIPID ANTIBODY;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; VASCULAR ENDOTHELIAL CELL; BLOOD; IMMUNOLOGY; MIDDLE AGED; YOUNG ADULT;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; COMPLEMENT ACTIVATION; FEMALE; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 85020844051     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2017.06.014     Document Type: Article

References (35)

1. Miyakis, S., Lockshin, M.D., Atsumi, T., Branch, D.W., Brey, R.L., Cervera, R., Derksen, R.H., PG, D.E.G., Koike, T., Meroni, P.L., Reber, G., Shoenfeld, Y., Tincani, A., Vlachoyiannopoulos, P.G., Krilis, S.A., International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4:2 (2006), 295–306.
2. Cervera, R., Rodriguez-Pinto, I., Colafrancesco, S., Conti, F., Valesini, G., Rosario, C., Agmon-Levin, N., Shoenfeld, Y., Ferrao, C., Faria, R., Vasconcelos, C., Signorelli, F., Espinosa, G., 14th international congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome. Autoimmun. Rev. 13:7 (2014), 699–707.
3. Chighizola, C.B., Ubiali, T., Meroni, P.L., Treatment of thrombotic antiphospholipid syndrome: the rationale of current management-an insight into future approaches. J Immunol Res, 2015, 2015, 951424.
4. van den Hoogen, L.L., van Roon, J.A., Radstake, T.R., Fritsch-Stork, R.D., Derksen, R.H., Delineating the deranged immune system in the antiphospholipid syndrome. Autoimmun. Rev. 15:1 (2016), 50–60.
5. Brock, C.O., Brohl, A.S., Obican, S.G., Incidence, pathophysiology, and clinical manifestations of antiphospholipid syndrome. Birth Defects Res. C Embryo Today Rev. 105:3 (2015), 201–208.
6. Mackworth-Young, C.G., Antiphospholipid syndrome: multiple mechanisms. Clin. Exp. Immunol. 136:3 (2004), 393–401.
7. Oku, K., Nakamura, H., Kono, M., Ohmura, K., Kato, M., Bohgaki, T., Horita, T., Yasuda, S., Amengual, O., Atsumi, T., Complement and thrombosis in the antiphospholipid syndrome. Autoimmun. Rev. 15:10 (2016), 1001–1004.
8. Shoenfeld, Y., Meroni, P.L., Toubi, E., Antiphospholipid syndrome and systemic lupus erythematosus: are they separate entities or just clinical presentations on the same scale?. Curr. Opin. Rheumatol. 21:5 (2009), 495–500.
9. Meroni, P.L., Borghi, M.O., Raschi, E., Tedesco, F., Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat. Rev. Rheumatol. 7:6 (2011), 330–339.
10. Rand, J.H., Wu, X.X., Andree, H.A., Ross, J.B., Rusinova, E., Gascon-Lema, M.G., Calandri, C., Harpel, P.C., Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a “lupus procoagulant” phenomenon. Blood 92:5 (1998), 1652–1660.
11. Arad, A., Proulle, V., Furie, R.A., Furie, B.C., Furie, B., beta(2)-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood 117:12 (2011), 3453–3459.
12. Conway, E.M., Reincarnation of ancient links between coagulation and complement. J. Thromb. Haemost. 13:Suppl. 1 (2015), S121–S132.
13. Arachchillage, D.R., Laffan, M., Pathogenesis and management of antiphospholipid syndrome. Br. J. Haematol., 2017.
14. Muller-Calleja, N., Lackner, K.J., Mechanisms of cellular activation in the antiphospholipid syndrome. Seminars in Thrombosis and Hemostasis, 2017.
15. Breen, K.A., Seed, P., Parmar, K., Moore, G.W., Stuart-Smith, S.E., Hunt, B.J., Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome. Thromb. Haemost. 107:3 (2012), 423–429.
16. Devreese, K.M., Hoylaerts, M.F., Is there an association between complement activation and antiphospholipid antibody-related thrombosis?. Thromb. Haemost. 104:6 (2010), 1279–1281.
17. Oku, K., Atsumi, T., Bohgaki, M., Amengual, O., Kataoka, H., Horita, T., Yasuda, S., Koike, T., Complement activation in patients with primary antiphospholipid syndrome. Ann. Rheum. Dis. 68:6 (2009), 1030–1035.
18. Arachchillage, D.R., Mackie, I.J., Efthymiou, M., Chitolie, A., Hunt, B.J., Isenberg, D.A., Khamashta, M., Machin, S.J., Cohen, H., Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism. J. Thromb. Haemost. 14:11 (2016), 2177–2186.
19. Fischetti, F., Durigutto, P., Pellis, V., Debeus, A., Macor, P., Bulla, R., Bossi, F., Ziller, F., Sblattero, D., Meroni, P., Tedesco, F., Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 106:7 (2005), 2340–2346.
20. Meroni, P.L., Macor, P., Durigutto, P., De Maso, L., Gerosa, M., Ferraresso, M., Borghi, M.O., Mollnes, T.E., Tedesco, F., Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. Blood 127:3 (2016), 365–367.
21. Picceli, V.F., Skare, T.L., Nisihara, R.M., Nass, F.R., Messias-Reason, I.T., Utiyama, S.R., BF*F allotype of the alternative pathway of complement: A marker of protection against the development of antiphospholipid antibodies in patients with systemic lupus erythematosus. Lupus 25:4 (2016), 412–417.
22. Agostinis, C., Durigutto, P., Sblattero, D., Borghi, M.O., Grossi, C., Guida, F., Bulla, R., Macor, P., Pregnolato, F., Meroni, P.L., Tedesco, F., A non-complement-fixing antibody to beta2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood 123:22 (2014), 3478–3487.
23. Romay-Penabad, Z., Carrera Marin, A.L., Willis, R., Weston-Davies, W., Machin, S., Cohen, H., Brasier, A., Gonzalez, E.B., Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies. Lupus 23:12 (2014), 1324–1326.
24. Lonze, B.E., Singer, A.L., Montgomery, R.A., Eculizumab and renal transplantation in a patient with CAPS. N. Engl. J. Med. 362:18 (2010), 1744–1745.
25. Shapira, I., Andrade, D., Allen, S.L., Salmon, J.E., Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum. 64:8 (2012), 2719–2723.
26. Canaud, G., Kamar, N., Anglicheau, D., Esposito, L., Rabant, M., Noel, L.H., Guilbeau-Frugier, C., Sberro-Soussan, R., Del Bello, A., Martinez, F., Zuber, J., Rostaing, L., Legendre, C., Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am. J. Transplant. 13:8 (2013), 2179–2185.
27. Bertolaccini, M.L., Contento, G., Lennen, R., Sanna, G., Blower, P.J., Ma, M.T., Sunassee, K., Girardi, G., Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome. J. Autoimmun., 2016.
28. Roubey, R.A., Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other “antiphospholipid” autoantibodies. Blood 84:9 (1994), 2854–2867.
29. Shoenfeld, Y., Etiology and pathogenetic mechanisms of the anti-phospholipid syndrome unraveled. Trends Immunol. 24:1 (2003), 2–4.
30. Taatjes, D.J., Bouffard, N., von Turkovich, M., Quinn, A.S., Wu, X.X., Vasovic, L.V., Rand, J.H., Visualization of macro-immune complexes in the antiphospholipid syndrome by multi-modal microscopy imaging. Micron 100 (2017), 23–29.
31. Barbhaiya, M., Andrade, D., Erkan, D., Aps, A., AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION): 5-year update. Curr. Rheumatol. Rep., 18(10), 2016, 64.
32. Cohen, D., Buurma, A., Goemaere, N.N., Girardi, G., le Cessie, S., Scherjon, S., Bloemenkamp, K.W., de Heer, E., Bruijn, J.A., Bajema, I.M., Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss. J. Pathol. 225:4 (2011), 502–511.
33. Gropp, K., Weber, N., Reuter, M., Micklisch, S., Kopka, I., Hallstrom, T., Skerka, C., beta(2)-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator. Blood 118:10 (2011), 2774–2783.
34. de Laat, B., Derksen, R.H., van Lummel, M., Pennings, M.T., de Groot, P.G., Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood 107:5 (2006), 1916–1924.
35. Noris, M., Galbusera, M., Gastoldi, S., Macor, P., Banterla, F., Bresin, E., Tripodo, C., Bettoni, S., Donadelli, R., Valoti, E., Tedesco, F., Amore, A., Coppo, R., Ruggenenti, P., Gotti, E., Remuzzi, G., Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 124:11 (2014), 1715–1726.